



## Press Release

### **Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets**

**Mumbai, India, July 31, 2008** - Lupin Limited, announced today that its subsidiary in the US, Lupin Pharmaceuticals, Inc. (LPI) has received final approval for the Company's Abbreviated New Drug Application (ANDA) for **Divalproex Sodium Delayed-Release Tablets**, 125 mg, 250 mg and 500 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced.

Lupin's Divalproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories' Depakote® tablets. Depakote had annual sales of approximately \$803 million for the twelve months ended March 2008, based on IMS Health sales data.

With the approval of Divalproex Sodium Delayed-Release Tablets, the cumulative ANDA approvals of the Company stand at 31 (including 3 tentative approvals) with 34 pending approvals from the USFDA.

#### **About Lupin**

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardio-vasculars (prils and statins), Diabetology, Asthma and NSAIDs.

For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US\$ 694 million) and Rs.4,083 million (US\$ 102 million) respectively. Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited which is among the top six Pharmaceutical companies in India. Through its sales and marketing headquarters in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

*Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:*

*This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.*

*\*Depakote® is a registered trademark of Abbott Laboratories.*

For further information please contact:

Lupin Limited:

Seema Ahuja

Head, Corporate Communications

Ph: 9920042046

Email:seemaahuja@lupinpharma.com

OR

Source PR:

Archana Pradhan

9820330505

Email: archanapradhan@sourcepr.com